ATS 2026: Long-term data show durable benefit of Trikafta for cystic fibrosis

Pharmaceutical Technology

48 weeks of Trikafta treatment improved lung capacity and inflammation biomarkers among CF patients.

pharminent May 21, 2026 (Last updated: May 21, 2026)

Pharmaceutical Technology

48 weeks of Trikafta treatment improved lung capacity and inflammation biomarkers among CF patients.

Related Stories